CDC5L

Cell division cycle 5-like protein · Q99459 · CDC5L on Sugi Atlas →

0 patent compounds predicted against CDC5L, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to CDC5L by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
Novel Peptide Vaccination for Patients With Advanced Prostate Cancer PHASE1/PHASE2UNKNOWN
Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor PHASE1/PHASE2NOT_YET_RECRUITING
Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and AMD3100 PHASE1/PHASE2COMPLETED
INCB018424 in Patients With Advanced Hematologic Malignancies PHASE2COMPLETED
Peptide Vaccine Focusing on Prevention of the Recurrence for Bladder Cancer PHASE2UNKNOWN
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE) PHASE1/PHASE2NOT_YET_RECRUITING
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma PHASE1/PHASE2COMPLETED
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Peptide Vaccine Targeting to Cancer Specific Antigen Combined With Anti-angiogenic Peptide Antigen in Treating Patients With Non-small Cell Lung Cancer PHASE1COMPLETED
Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Esophageal Cancer PHASE1COMPLETED
Phase I Study to Assess the Safety, Pharmacokinetics, & Pharmacodynamics of GSK923295 in Subjects w/ Refractory Cancer PHASE1COMPLETED
Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Gastric Cancer PHASE1COMPLETED
Novel Peptide Vaccination for Patients With Advanced Bladder Cancer PHASE1COMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Study of the Effect of Innate on the Inflammatory Response to Endotoxin nanRECRUITING
PCD New Gene Discovery nanCOMPLETED
Telomeres Length in Israeli Fibrotic ILD Patients nanENROLLING_BY_INVITATION
Study of the Pathophysiological Mechanisms Involved in Bleeding Events nanCOMPLETED
DCLK1 as a Marker/Indicator of Stem Cell Response in Barrett's Esophagus/Esophageal Adenocarcinoma nanCOMPLETED
Genetics of Primary Ciliary Dyskinesia nanCOMPLETED
Regulation of Vitamin D Receptor (VDR),Calcium Sensing Receptor (CaSR), Cyclin D1,Ki67 and Proliferating Cell Nuclear Antigen (PCNA) in Primary Hyperparathyroidism nanUNKNOWN
Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders nanWITHDRAWN
Immunogenetics of Visceral Leishmaniasis nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Ischemic Preconditioning - Perspectives of Use Vivio/in Vitro Studies nanENROLLING_BY_INVITATION
Genetic Susceptibility in MAlignant Pleural Mesothelioma: Clinical Implication of GermliNE variaTionS nanRECRUITING
Hereditary Nonpolyposis Colorectal Cancer in Taiwan-Related Genetic Study and Clinical Applications nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a CDC5L binder may also engage these)

ProteinNameSimilarity
Q6A068 1.000 Q6A068 →
Q2KJC1 1.000 Q2KJC1 →
O08837 1.000 O08837 →
P92948 1.000 P92948 →
A7SD85 1.000 A7SD85 →
Q4WHG0 0.993 Q4WHG0 →
Q4P652 0.991 Q4P652 →
Q7SAF6 0.991 Q7SAF6 →
Q52G60 0.988 Q52G60 →
P0CO94 0.986 P0CO94 →
C8VBH3 0.986 C8VBH3 →
P39964 0.985 P39964 →
Q5ZKI4 0.984 Q5ZKI4 →
CDC37 Hsp90 co-chaperone Cdc37 0.983 landscape →
Q803J8 0.983 Q803J8 →
Q51LS1 0.983 Q51LS1 →
P19351 0.983 P19351 →
Q9NZ63 0.982 Q9NZ63 →
Q3TQI7 0.982 Q3TQI7 →
E1C760 0.982 E1C760 →
Q4R6Y7 0.981 Q4R6Y7 →
B4HMY3 0.981 B4HMY3 →
Q96AJ1 0.981 Q96AJ1 →
Q9DGQ7 0.981 Q9DGQ7 →
Q0VC06 0.981 Q0VC06 →
Q5R8B2 0.981 Q5R8B2 →
Q96GA3 0.981 Q96GA3 →
Q7PGE8 0.981 Q7PGE8 →
Q8R3P7 0.981 Q8R3P7 →
Q5RC87 0.980 Q5RC87 →